Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610072 · ClinicalTrials.gov registry record · Early Phase 1
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
A Early Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, sponsored by William Stoops.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05610072: Recruiting Early Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, sponsored by William Stoops.
NCT05610072 is a Early Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder that is actively recruiting participants, run by William Stoops. The registered enrollment target is 24 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05610072, a Early Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, is actively recruiting participants, sponsored by William Stoops.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate glutamatergic dysregulation, and thus will reduce both opioid and cocaine demand. These hypotheses will be tested with two specific aims. Specific Aim 1. Determine the reinforcing effects of cocaine in individuals with comorbid opioid and cocaine use disorder with physiological dependence on opioids during NAC maintenance. All subjects will be maintained on oral hydromorphone. They will also be randomly assigned to receive placebo or oral NAC (2.4 g/day), stratified by sex. After dose stabilization, experimental sessions will be conducted in which subjects complete hypothetical cocaine purchase tasks during opioid maintenance and opioid withdrawal. The hypotheses are: 1) cocaine purchasing will be greater during opioid withdrawal and 2) NAC maintenance will attenuate cocaine purchasing across opioid maintenance and withdrawal periods. Specific Aim 2. Evaluate glutamate functionality during periods of opioid maintenance and withdrawal in individuals with comorbid opioid and cocaine use disorder and physiological dependence on opioids during NAC maintenance. Subjects will undergo magnetic resonance spectroscopy to evaluate brain glutamate changes as a function of opioid maintenance/withdrawal state and NAC maintenance. The hypotheses are: 1) glutamate levels will be elevated during opioid withdrawal and 2) NAC maintenance will ameliorate elevated glutamate levels.
Primary Outcome
Amount of opioids purchased on a hypothetical purchase task
Conditions Studied
Interventions
- DRUG Hydromorphone
- DRUG n-acetylcysteine
- DRUG Placebo n-acetylcystine
- DRUG Placebo hydromorphone
Study Locations (2)
Kentucky
- University of Kentucky Laboratory of Human Behavioral Pharmacology - Lexington
- University of Kentucky Department of Behavioral Science - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT05610072 shows while recruiting
NCT05610072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Hydromorphone is the first listed.
NCT05610072 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT05610072 about?
NCT05610072 is a clinical study titled "Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)". The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate glutamatergic dysregulation, and thus will reduce b...
What is the current status of trial NCT05610072?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2022-12-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05610072 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Cocaine Use Disorder, Stimulant Use Disorder.
What interventions are being tested in trial NCT05610072?
The interventions under investigation include: Hydromorphone (DRUG), n-acetylcysteine (DRUG), Placebo n-acetylcystine (DRUG), Placebo hydromorphone (DRUG).
Who is sponsoring clinical trial NCT05610072?
This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610072 being conducted?
This trial has 2 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05610072's enrollment target sits among peer trials
24 222nd of 257 higher than 31 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
RECRUITING · Early Phase 1
-
Cannabidiol in Opioid Use Disorder and Chronic Pain
RECRUITING · Early Phase 1
-
Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People
ACTIVE NOT RECRUITING · Early Phase 1
-
Enhancing Prospective Thinking in Early Recovery (PARK)
COMPLETED · Early Phase 1
-
Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment
COMPLETED · Early Phase 1
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI